Facebook
Twitter
LinkedIn
Forward4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies
The 4th Binaytara Precision Oncology Summit is an annual 2-day CME-accredited national conference that offers an unparalleled opportunity for oncology professionals to delve into the latest advancements, innovations, and practices in precision oncology. The theme for this year's summit, "Current Standards and Emerging Therapies," highlights the conference's commitment to providing a comprehensive overview of the field, including in-depth discussions on the latest developments in precision oncology, alongside a thorough examination of established treatment protocols. Focus on actionable mutations ensures that the presented information translates directly into improved patient care.
The summit features didactics, panel discussions, interactive case studies, and scientific abstract presentations.
This conference will augment healthcare providers' foundation of knowledge and clinical competence in several areas, including:
- Integrating different platforms available for testing actionable molecular alterations to identify targeted therapy options.
- Current and evolving paradigms in precision oncology approach for management of common malignancies.
- Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.
Target Audience
- Hematologists/Oncologists
- Oncology Nurse Practitioners
- Oncology Pharmacists
- Oncology Physician Assistants
- Oncology Fellows/Residents
- Oncology Nurses
- Researchers and others involved in the care of cancer patients
Organizing Committee
Program Director:
Dr. Binay Shah - Binaytara Foundation
Conference Chair:
Dr. Charles M. Perou - UNC Lineberger Comprehensive Cancer Center
Conference Co-Chairs:
Dr. Mark Pegram - Stanford University
Dr. James Ford - Stanford University
Organizing Committee:
Dr. Siddhartha Yadav - Mayo Clinic
Dr. Jonathan Wesley Riess - UC Davis
Dr. Shivaani Kummar - Oregon Health & Science University
Dr. Diwakar Davar - UPMC Hillman Cancer Center
Dr. Christopher T. Chen - Stanford University
Dr. Shailender Bhatia - Fred Hutchinson Cancer Center / University of Washington
Dr. Pamela Munster - UCSF Helen Diller Family Comprehensive Cancer Center
Abstract Committee Chairs
Dr. Jonathan Wesley Riess - UC Davis
Dr. Marianne E. Dubard-Gault - Swedish Health Services
Abstract Committee
Dr. Mridula Krishnan - University of Nebraska Medical Center
Dr. Rajat Thawani - UChicago Medicine
Dr. Shipra Gandhi - Roswell Park Comprehensive Cancer Center
Dr. Matthew Schwede - Swedish Cancer Institute
Dr. Nicholas Mitsiades - UC Davis
Dr. Fatemeh Ardeshir-Larijani - Emory Winship Cancer Institute
Dr. Arya Mariam Roy - Roswell Park Comprehensive Cancer Center
Learning Objectives
Upon successful completion of this educational activity on precision oncology, participants will be able to:
- Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
- Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
- Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies.
- Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
- Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in a clinical investigation for cancer patients.
HOTEL INFORMATION
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
DAY 1 - OCTOBER 5th, 2024
All times listed in Pacific Daylight Time (PDT).
07:00 AM – 07:45 AM Registration, Breakfast, & Exhibits
07:45 AM – 07:50 AM Welcome
07:50 AM – 08:00 AM Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital In Nepal - Justin Marquart
08:00 AM – 09:00 AM Session 1: Beyond NGS: Tools in Precision Oncology
Session Chair: Christopher T. Chen, MD
08:00 AM – 08:15 AM WGS, WES, and Mutational Signatures for Identification of Complex Genomic Alterations Driving Cancer Development and Progression - Hanlee P. Ji, MD
08:15 AM – 08:30 AM Potential Clinical Application(s) of Transcriptomics and Proteomics - Christopher T. Chen, MD
08:30 AM – 08:45 AM CTCs and ctDNA to Aid Therapeutic Decisions and Surveillance - Ash A. Alizadeh, MD, PhD
08:45 AM – 09:00 AM Discussion
09:00 AM – 10:00 AM Session 2: DNA-Repair Deficiencies and Genomic Instability
Session Chair: James M. Ford, MD, FASCO
09:00 AM – 09:15 AM Biomarkers of DNA-Repair Deficiencies, HRD, and Genomic Instability - Joshua Gruber, MD, PhD
09:15 AM – 09:30 AM Translational Research Landscape for HR Deficient and Genomically Unstable Tumors - Shridar Ganesan, MD, PhD
09:30 AM – 09:45 AM Next Generation of DNA-Repair Deficiency Targeted Treatments - Michael Cecchini, MD
09:45 AM – 10:00 AM Discussion
10:00 AM – 10:30 AM Break & Exhibits
10:30 AM – 11:45 AM Session 3: Cancer Immunotherapy
Session Chair: Diwakar Davar, MD
10:30 AM – 10:45 AM Cancer Vaccines - Kiran Dhillon, PhD
10:45 AM – 11:00 AM Innate Immune Signaling Pathways: How to Turn ‘Cold’ Tumors into ‘Hot’ Ones? - Diwakar Davar, MD
11:00 AM – 11:15 AM Predicting Response/Resistance to Immune Checkpoint Inhibitors - Isaac Chan, MD, PhD
11:15 AM – 11:30 AM Engineering Immune Cells to Treat Cancer (CAR-Ts and Beyond) - Bryan Choi, MD, PhD
11:30 AM – 11:45 AM Discussion
11:45 AM – 01:00 PM Lunch & Exhibits
12:00 PM – 12:45 PM: Product Theater Sponsored by Merck in Breakout room
Topic: A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
Speaker:
* This is a non-CME activity *
01:00 PM – 01:45 PM Session 4: Keynote
01:00 PM – 01:30 PM Keynote Lecture - Glen N. Barber, PhD
01:30 PM – 01:45 PM Discussion
01:45 PM – 02:45 PM Session 5: RAS/RAF/MAPK and PI3 Kinase/AKT/mTOR Signaling
Session Chair: Shailender Bhatia, MD
01:45 PM – 02:00 PM Therapeutic Opportunities Leveraging Aberrant RAS/RAF/MAPK Signaling - Ken Westover, MD, PhD
02:00 PM – 02:15 PM Therapeutic Opportunities Leveraging Aberrant PI3 Kinase/AKT/mTOR Signaling - Neil M. Iyengar, MD
02:15 PM – 02:30 PM Resistance Mechanisms and Challenges to Targeting RAS/RAF/MAPK and PI3 Kinase/AKT/mTOR Pathways - Roger S. Lo, MD, PhD
02:30 PM – 02:45 PM Discussion
02:45 PM – 03:45 PM Session 6: Hormone Receptor Signaling
Session Chair: Matthew Ellis, MB, BChir, PhD, FRCP
02:45 PM – 03:00 PM Advances in Estrogen Receptor Signaling and Biology - Matthew Ellis, MB, BChir, PhD, FRCP
03:00 PM – 03:15 PM Therapeutic Options for ESR1-Mutant Breast Cancers - Kelly E. McCann, MD, PhD
03:15 PM – 03:30 PM Treatment Strategies Targeting the Androgen Receptor - Evan Y. Yu, MD
03:30 PM – 03:45 PM Discussion
03:45 PM – 05:45 PM Session 7: Oral Abstracts & Networking
Session Chairs: Jonathan Wesley Riess, MD, MS and Marianne E. Dubard-Gault, MD, MS
* This is a Non-CME activity *
DAY 2 - OCTOBER 6th, 2024
07:00 AM – 08:15 AM Session 8: Poster Abstracts & Breakfast
Session Chairs: Jonathan Wesley Riess, MD, MS and Marianne E. Dubard-Gault, MD, MS
* This is a Non-CME activity *
08:15 AM – 09:30 AM Session 9: Targeting Receptor Tyrosine Kinases
Session Chair: Jonathan Wesley Riess, MD, MS
08:15 AM – 08:30 AM Biology of Receptor Tyrosine Kinases as Drivers of Cancer Pathogenesis - Trever G. Bivona, MD, PhD
08:30 AM – 08:45 AM A Primer on Tyrosine Kinase Inhibitors and Implications for Management of EGFR, ALK, ROS1, MET and RET Altered Tumors - Christina S. Baik, MD, MPH
08:45 AM – 09:00 AM HER2 Signaling in Breast and Other Cancers, and Implications for Treatment - Mark Pegram, MD
09:00 AM – 09:15 AM Overcoming Challenges in Targeting Receptor Tyrosine Kinases and Resistance Mechanisms - Xiuning Le, MD, PhD
09:15 AM – 09:30 AM Discussion
09:30 AM – 10:45 AM Session 10: Molecular Tumor Board
Session Chair: Siddhartha Yadav, MBBS, MD
09:30 AM – 09:45 AM Classical EGFR Mutation Positive Lung Cancer; Management over Multiple Lines of Therapy - Deepti Behl, MD
09:45 AM – 10:00 AM Case 2 - Sant P. Chawla, MD
10:00 AM – 10:15 AM ALK-Positive Non-Small Cell Lung Cancer - Kim-Son Nguyen, MD, MPA
10:15 AM – 10:30 AM BRCA2 and Esophageal Cancer - Marianne E. Dubard-Gault, MD, MS
10:30 AM – 10:45 AM Case 5
10:45 AM – 11:00 AM Break & Exhibits
11:00 AM – 12:00 PM Session 11: Cancer Interception and Prevention
Session Chair: Marianne E. Dubard-Gault, MD, MS
11:00 AM – 11:15 AM Multi-Cancer Early Detection Tests – Clinical Utility and Pitfalls - Margaret Tempero, MD
11:15 AM – 11:30 AM Personalized Vaccines for Primary or Secondary Cancer Prevention - Keith L. Knutson, PhD
11:30 AM – 11:45 AM Precision in Cancer Risk Prediction Incorporating Genetic, Hormonal, and Environmental Risk Factors: Implications for Cancer Prevention - Fergus J. Couch, PhD
11:45 AM – 12:00 PM Discussion
12:00 PM – 01:00 PM Lunch & Exhibits
01:00 PM – 02:00 PM Session 12: Precision Oncology Drug Development (Part 1)
Session Chair: Shivaani Kummar, MD, FACP
01:00 PM – 01:20 PM Identifying Predictive Markers of Response and Resistance in Cancer Therapeutics - Shivaani Kummar, MD, FACP
01:20 PM – 01:35 PM Role of AI in Oncology Drug Development
01:35 PM – 01:50 PM How to Design Precision Clinical Trials for the Rare Targets - Ying Lu, PhD
01:50 PM – 02:00 PM Discussion
02:00 PM – 03:00 PM Session 13: Precision Oncology Drug Development (Part 2)
Session Chair: Pamela Munster, MD
02:00 PM – 02:15 PM Antibody-Drug Conjugates: Opportunities and Challenges - Arlene O. Siefker-Radtke, MD
02:15 PM – 02:30 PM Cellular Therapy: Where Do We Stand Now? - Krishna Komanduri, MD
02:30 PM – 02:45 PM Bispecific Antibodies: Opportunities and Challenges - Omid Hamid, MD
02:45 PM – 03:00 PM Quantitative Medicine for Breast Cancer Patients - Charles M. Perou, PhD
03:00 PM – 03:15 PM Discussion
03:15 PM – 03:30 PM Closing Remarks
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Charles Perou
Shailender Bhatia, MD
James Ford, MD, FASCO
Jonathan Riess, MD, MS
Ash Alizadeh, MD/PhD; Moghadam Family Professor of Medicine (Oncology), Stanford University School of Medicine
Christina Baik, MD MPH
Omid Hamid
Keith Knutson
Kelly McCann, MD, PhD
Mark Pegram, MD
DEEPTI BEHL, M.D.
Shipra Gandhi, MD, MS
Mridula Krishnan
Mark Pegram, MD
Arya Mariam Roy, MD
Matthew Schwede, MD, MS
Rajat Thawani, MD
Available Credit
- 11.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 11.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 11.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.50 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.